Shedding Light on PARP Inhibitor Response through Functional Imaging. Editorial Article uri icon

Overview

abstract

  • Functional PET imaging using a PARP inhibitor (PARPi) analog may serve as an early, dynamic biomarker of response to PARPi therapy in high-grade serous ovarian cancer. Clinically, this could help to rapidly identify PARPi nonresponders, thereby maximizing efficacy and avoiding toxicities of futile treatments. See related article by Pantel et al., p. 1515.

publication date

  • April 14, 2023

Research

keywords

  • Antineoplastic Agents
  • Ovarian Neoplasms

Identity

PubMed Central ID

  • PMC10106371

Scopus Document Identifier

  • 85152595647

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2021.08.024

PubMed ID

  • 36700799

Additional Document Info

volume

  • 29

issue

  • 8